title: Diphenyl diselenide protects rat hippocampal slices submitted to oxygen-glucose deprivation and diminishes inducible nitric oxide synthase immunocontent.
abstract: Diphenyl diselenide (PhSe)2 is an organic selenium compound that has been little studied. In this study we investigated the effects of (PhSe)2 (0.1-3 microM) in a classical model of in vitro brain ischemia, which consists of exposing rat hippocampal slices to oxygen-glucose deprivation (OGD). Hippocampal slices were exposed for 60 min to OGD and the cellular viability (performed by MTT assay) as well as the immunocontent of nitric oxide synthase inducible (iNOS) were evaluated after 180 min of a recovery period. OGD decreased cellular viability by 50% and increased more than twice the immunocontent of iNOS of hippocampal slices. (PhSe)2 (1 and 3 microM) added during OGD and the recovery period abolished both effects. These results demonstrate for the first time the neuroprotective effects of (PhSe)2. Although the selenium analog--ebselen--has been widely used in ischemia models, our results suggest that other selenoorganic compounds could be investigated as pharmacological tools against brain disorders.
authors.affiliation: Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo, Porto Alegre/RS, 90035-003 Brazil
authors.forename: Gabriele
authors.initials: G
authors.lastname: Ghisleni
authors.forename: Lisiane O
authors.initials: LO
authors.lastname: Porciúncula
authors.forename: Helena
authors.initials: H
authors.lastname: Cimarosti
authors.forename: João
authors.initials: J
authors.lastname: Batista T  Rocha
authors.forename: Christianne G
authors.initials: CG
authors.lastname: Salbego
authors.forename: Diogo O
authors.initials: DO
authors.lastname: Souza
mesh_terms: D000818:Animals; D001555:Benzene Derivatives / Q000494:pharmacology*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000172:deficiency; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D009924:Organ Culture Techniques; D016566:Organoselenium Compounds / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001555:Benzene Derivatives; D018696:Neuroprotective Agents; D016566:Organoselenium Compounds; C061132:diphenyldiselenide; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D005947:Glucose